NCT05931302View on ClinicalTrials.gov

Initial Staging of Lobular Breast Carcinoma: Head to Head Comparison of 68Ga-FAPI-46 and 18F-FDG PET/CT

NAActive, not recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

November 16, 2023

Primary Completion Date

November 30, 2026

Study Completion Date

November 30, 2026

Conditions
Lobular Breast Carcinoma
Interventions
DIAGNOSTIC_TEST

68Ga-FAPI-46 PET scan

"68Ga-FAPI-46 is a radiotracer for the detection of Fibroblast Activation Protein (FAP) in cancer patients.~68Ga-FAPI-46 will be administered intravenously at a dose of 2MBq/kg. Patients will be scanned 60 minutes after administration of 68Ga-FAPI-46."

Trial Locations (1)

98000

Centre Hospitalier Princesse Grace, Monaco

All Listed Sponsors
collaborator

Institut Curie

OTHER

collaborator

Centre Antoine Lacassagne

OTHER

lead

Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer

OTHER

NCT05931302 - Initial Staging of Lobular Breast Carcinoma: Head to Head Comparison of 68Ga-FAPI-46 and 18F-FDG PET/CT | Biotech Hunter | Biotech Hunter